Related Experiment Video
Updated: Sep 21, 2025
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
Testosterone analysis in prostate cancer patients
Lennart J van Winden1, Huub H van Rossum1
1Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract:
Testosterone is an essential steroid hormone associated with a wide variety of biological processes in humans. In prostate cancer, androgen signaling is an important driver of tumor cell growth. Depletion of gonadal testosterone, achieved by surgical or chemical castration, prevents androgenic signaling and temporally reduces, stops or reverses tumor growth before inevitable progression to castration-resistant prostate cancer occurs. Additional treatment strategies targeting androgenic signaling have become available, although these are without curative intent. While circulating testosterone is also associated with disease risk and potential clinical utility, the main use in the clinical lab is monitoring adequate castration and subsequent resistance to therapy. Adequate castrate testosterone concentrations are currently based on over 50 year-old double-isotope derivative assays that are disputed in automated immunoassay (IA) analysis. The debate has been further fueled with the introduction of mass spectrometry-based assays for testosterone, offering a substantial increase in sensitivity and specificity. In this review, we discuss testosterone regulation and androgen deprivation therapy in prostate cancer. We provide an overview of the developments in testosterone analysis for monitoring adequate castration and resistance to therapy. Current clinical practice and future clinical utility will be discussed. Finally, clinical and research recommendations will be presented.
Insights
This review covers testosterone regulation and androgen deprivation therapy for prostate cancer. It examines evolving testosterone testing methods for monitoring castration resistance, crucial for effective treatment.
Area of Science:
- Endocrinology
- Oncology
- Clinical Chemistry
Background:
- Testosterone is a key steroid hormone influencing biological processes and driving prostate cancer growth via androgen signaling.
- Androgen deprivation therapy (ADT) aims to deplete testosterone, slowing tumor progression before castration resistance develops.
- Current methods for measuring castrate testosterone levels are outdated and debated, especially with new assay technologies.
Purpose of the Study:
- To review testosterone regulation and ADT in prostate cancer.
- To provide an overview of evolving testosterone analysis methods for monitoring castration and resistance.
- To discuss current clinical practices, future utility, and provide recommendations for testosterone testing.
Main Methods:
- Literature review of testosterone regulation, ADT, and testosterone assay development.
- Analysis of current clinical practices and emerging mass spectrometry-based testosterone assays.
- Discussion of the clinical utility and research implications of improved testosterone measurement.
Main Results:
- ADT is a cornerstone in managing prostate cancer by reducing androgen signaling.
- Existing testosterone assays for monitoring castration are suboptimal, leading to clinical debate.
- Newer mass spectrometry assays offer improved sensitivity and specificity for testosterone measurement.
Conclusions:
- Accurate testosterone monitoring is critical for effective ADT in prostate cancer.
- Advancements in testosterone assay technology are essential for reliable clinical decision-making.
- Standardized, validated testosterone assays are needed to guide prostate cancer therapy and research.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
